Cargando…
Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
BACKGROUND: Recent studies have revealed that bevacizumab (BEV) can improve the survival of patients with newly diagnosed unresectable glioblastoma (GBM) with poor performance status. For patients who develop early clinical deterioration, early initiation of BEV would be beneficial. However, the saf...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Scientific Scholar
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805652/ https://www.ncbi.nlm.nih.gov/pubmed/36600767 http://dx.doi.org/10.25259/SNI_959_2022 |